Therapy-related myeloid neoplasms following treatment with PARP inhibitors: new molecular insights

J. E. Martin; S. Khalife-Hachem; T. Grinda; M. Kfoury; S. Garciaz; F. Pasquier; J. Vargaftig; M. Uzunov; A. Belhabri; S. Bertoli; S. Cotteret; V. Vergé; A. Renneville; F. Rosselli; I. Antony-Debre; E. Rouleau; F. Salviat; O. Caron; S. Delaloge; P. Pautier; G. Etienne; C. Recher; N. Vey; S. De Botton; A. Leary; C. Marzac; J. B. Micol

doi:10.1016/j.annonc.2021.04.015

Therapy-related myeloid neoplasms following treatment with PARP inhibitors: new molecular insights

J. E. Martin, S. Khalife-Hachem, T. Grinda, M. Kfoury, S. Garciaz, F. Pasquier, J. Vargaftig, M. Uzunov, A. Belhabri, S. Bertoli, S. Cotteret, V. Vergé, A. Renneville, F. Rosselli, I. Antony-Debre, E. Rouleau, F. Salviat, O. Caron, S. Delaloge, P. PautierG. Etienne, C. Recher, N. Vey, S. De Botton, A. Leary, C. Marzac, J. B. Micol

Résultats de recherche: Contribution à un journal › Letter › Revue par des pairs

18 Citations (Scopus)

langue originale	Anglais
Pages (de - à)	1046-1048
Nombre de pages	3
journal	Annals of Oncology
Volume	32
Numéro de publication	8
Les DOIs	https://doi.org/10.1016/j.annonc.2021.04.015
état	Publié - 1 août 2021

Accès au document

10.1016/j.annonc.2021.04.015

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

Martin, J. E., Khalife-Hachem, S., Grinda, T., Kfoury, M., Garciaz, S., Pasquier, F., Vargaftig, J., Uzunov, M., Belhabri, A., Bertoli, S., Cotteret, S., Vergé, V., Renneville, A., Rosselli, F., Antony-Debre, I., Rouleau, E., Salviat, F., Caron, O., Delaloge, S., ... Micol, J. B. (2021). Therapy-related myeloid neoplasms following treatment with PARP inhibitors: new molecular insights. Annals of Oncology, 32(8), 1046-1048. https://doi.org/10.1016/j.annonc.2021.04.015

@article{c735bd6f9e44455b83f19c235a1af8de,

title = "Therapy-related myeloid neoplasms following treatment with PARP inhibitors: new molecular insights",

author = "Martin, {J. E.} and S. Khalife-Hachem and T. Grinda and M. Kfoury and S. Garciaz and F. Pasquier and J. Vargaftig and M. Uzunov and A. Belhabri and S. Bertoli and S. Cotteret and V. Verg{\'e} and A. Renneville and F. Rosselli and I. Antony-Debre and E. Rouleau and F. Salviat and O. Caron and S. Delaloge and P. Pautier and G. Etienne and C. Recher and N. Vey and {De Botton}, S. and A. Leary and C. Marzac and Micol, {J. B.}",

note = "Funding Information: This work was supported by a grant from Association Laurette Fugain [grant number ALF 2019/11 ] and French National Cancer Institute (INCa) PAIR gyneco grant [grant number 12-017]. Funding Information: This work was supported by a grant from Association Laurette Fugain [grant number ALF 2019/11] and French National Cancer Institute (INCa) PAIR gyneco grant [grant number 12-017]. JBM received honoraria from AbbVie, Jazz Pharmaceuticals, and Astellas outside the submitted work. CM received honoraria from Astellas outside the submitted work. AL reports fees to her institution for consulting from AstraZeneca, Clovis, GlaxoSmithKline, Biocad, Ability Pharma, Merck Serono, Tesaro, Merck Sharp & Dohme, Seattle Genetics, GamaMabs Pharma, and Gritstone Oncology; grants from Inivata and Sanofi; personal fees for consulting from Biocad, Gridstone Oncology, and Seattle Genetics; and non-financial support from AstraZeneca, Roche, Clovis, and Tesaro, outside the submitted work. SDB received honoraria from Agios, Celgene, Forma Therapeutics, AbbVie, Astellas, Daichi, Novartis, Pfizer, and Jazz Pharmaceuticals and has received research funding from Agios and Forma Therapeutics outside the submitted work. SD received honoraria from Pfizer, AstraZeneca, and Roche Genentech and has received research funding from Novartis, Pfizer, AstraZeneca, Roche Genentech, Lilly, Puma, Myriad, Orion, Amgen, Sanofi, Genomic Health, GE, Servier, MSD, BMS, and Pierre Fabre outside the submitted work. SB received grants from Astellas, Daiichi-Sankyo, Jazz Pharmaceuticals, and Sanofi. CR reported grants from Celgene, Amgen, Novartis, Jazz, AbbVie, Astellas, MaatPharma, Agios, Daiichi-Sankyo, and Roche; personal fees from Incyte, Macrogenics, Otsuka, Janssen, Pfizer, and Takeda; and non-financial support from Sanofi and Gilead outside the submitted work. GE received honoraria from Bristol Myers Squibb, Incyte, Pfizer, and Novartis and non-financial support from Pfizer and Novartis outside the submitted work. All other authors have declared no conflicts of interest.",

year = "2021",

month = aug,

day = "1",

doi = "10.1016/j.annonc.2021.04.015",

language = "English",

volume = "32",

pages = "1046--1048",

journal = "Annals of Oncology",

issn = "0923-7534",

number = "8",

}

Martin, JE, Khalife-Hachem, S, Grinda, T, Kfoury, M, Garciaz, S, Pasquier, F, Vargaftig, J, Uzunov, M, Belhabri, A, Bertoli, S, Cotteret, S, Vergé, V, Renneville, A, Rosselli, F, Antony-Debre, I, Rouleau, E, Salviat, F, Caron, O, Delaloge, S, Pautier, P, Etienne, G, Recher, C, Vey, N, De Botton, S, Leary, A, Marzac, C & Micol, JB 2021, 'Therapy-related myeloid neoplasms following treatment with PARP inhibitors: new molecular insights', Annals of Oncology, VOL. 32, Numéro 8, p. 1046-1048. https://doi.org/10.1016/j.annonc.2021.04.015

TY - JOUR

T1 - Therapy-related myeloid neoplasms following treatment with PARP inhibitors

T2 - new molecular insights

AU - Martin, J. E.

AU - Khalife-Hachem, S.

AU - Grinda, T.

AU - Kfoury, M.

AU - Garciaz, S.

AU - Pasquier, F.

AU - Vargaftig, J.

AU - Uzunov, M.

AU - Belhabri, A.

AU - Bertoli, S.

AU - Cotteret, S.

AU - Vergé, V.

AU - Renneville, A.

AU - Rosselli, F.

AU - Antony-Debre, I.

AU - Rouleau, E.

AU - Salviat, F.

AU - Caron, O.

AU - Delaloge, S.

AU - Pautier, P.

AU - Etienne, G.

AU - Recher, C.

AU - Vey, N.

AU - De Botton, S.

AU - Leary, A.

AU - Marzac, C.

AU - Micol, J. B.

N1 - Funding Information: This work was supported by a grant from Association Laurette Fugain [grant number ALF 2019/11 ] and French National Cancer Institute (INCa) PAIR gyneco grant [grant number 12-017]. Funding Information: This work was supported by a grant from Association Laurette Fugain [grant number ALF 2019/11] and French National Cancer Institute (INCa) PAIR gyneco grant [grant number 12-017]. JBM received honoraria from AbbVie, Jazz Pharmaceuticals, and Astellas outside the submitted work. CM received honoraria from Astellas outside the submitted work. AL reports fees to her institution for consulting from AstraZeneca, Clovis, GlaxoSmithKline, Biocad, Ability Pharma, Merck Serono, Tesaro, Merck Sharp & Dohme, Seattle Genetics, GamaMabs Pharma, and Gritstone Oncology; grants from Inivata and Sanofi; personal fees for consulting from Biocad, Gridstone Oncology, and Seattle Genetics; and non-financial support from AstraZeneca, Roche, Clovis, and Tesaro, outside the submitted work. SDB received honoraria from Agios, Celgene, Forma Therapeutics, AbbVie, Astellas, Daichi, Novartis, Pfizer, and Jazz Pharmaceuticals and has received research funding from Agios and Forma Therapeutics outside the submitted work. SD received honoraria from Pfizer, AstraZeneca, and Roche Genentech and has received research funding from Novartis, Pfizer, AstraZeneca, Roche Genentech, Lilly, Puma, Myriad, Orion, Amgen, Sanofi, Genomic Health, GE, Servier, MSD, BMS, and Pierre Fabre outside the submitted work. SB received grants from Astellas, Daiichi-Sankyo, Jazz Pharmaceuticals, and Sanofi. CR reported grants from Celgene, Amgen, Novartis, Jazz, AbbVie, Astellas, MaatPharma, Agios, Daiichi-Sankyo, and Roche; personal fees from Incyte, Macrogenics, Otsuka, Janssen, Pfizer, and Takeda; and non-financial support from Sanofi and Gilead outside the submitted work. GE received honoraria from Bristol Myers Squibb, Incyte, Pfizer, and Novartis and non-financial support from Pfizer and Novartis outside the submitted work. All other authors have declared no conflicts of interest.

PY - 2021/8/1

Y1 - 2021/8/1

UR - http://www.scopus.com/inward/record.url?scp=85109535158&partnerID=8YFLogxK

U2 - 10.1016/j.annonc.2021.04.015

DO - 10.1016/j.annonc.2021.04.015

M3 - Letter

C2 - 34107346

AN - SCOPUS:85109535158

SN - 0923-7534

VL - 32

SP - 1046

EP - 1048

JO - Annals of Oncology

JF - Annals of Oncology

IS - 8

ER -